IRON-CRT Trial: A Hint at Potential Mechanisms by Which Iron Repletion Improves Cardiac Function in ID Patients with HF

Recently published findings in the European Heart Journal detailed a randomized double-blind study titled “Effect of Intravenous Ferric Carboxymaltose on Reverse Remodelling Following Cardiac Resynchronization Therapy (IRON-CRT)” that investigated the use of intravenous ferric carboxymaltose (FCM) in symptomatic heart failure patients with reduced ejection fraction (HFrEF), who also had iron deficiency (ID), persistently reduced left ventricular ejection fraction (LVEF) and an implanted cardiac resynchronization therapy (CRT) device.

BUILDING ON EXISTING KNOWLEDGE

The present trial aimed to build on recent findings from the AFFIRM-AHF trial, in which researchers demonstrated the beneficial impact of intravenous FCM on reducing the recurrence of hospital readmissions in patients with HFrEF. Authors of IRON-CRT acknowledge the significance of the AFFIRM-AHF findings but point to the lack of knowledge specifically on the effect of FCM on cardiac function and structure, which they aimed to establish.

OBJECTIVE

The IRON-CRT trial intended to determine if intravenous FCM treatment would result in cardiac reverse remodeling (measure of cardiac structure) and demonstrate improved force-frequency relationship (measure of cardiac function) in patients with HFrEF.

DESIGN, PARTICIPANTS AND MEASURES

The IRON-CRT trial was designed and conducted by researchers from the Department of Cardiology at Hasselt University in Diepenbeek, Belgium. The study’s double-blind design ensured that researchers and participants were not aware of the study or placebo group until the completion of the trial. Of the 221 HFrEF participants evaluated for eligibility at two hospitals in Belgium, 75 were selected that met the study criteria of reduced LVEF, ID and CRT device implanted at least 6 months prior.
A web-based system randomized participants to receive either the regular standard care with saline placebo (n=38), or to receive intravenous FCM at study initiation and again 8 to 14 days later, if necessary, based on hemoglobin levels (n=37). Participants were treated with FCM or placebo saline only at baseline and then called back after 3 months for endpoint analysis. To ensure both investigators and participants were blind to which group was receiving FCM, measures were taken to camouflage the bags of either FCM or saline, as saline is a clear liquid while FCM is dark brown.

For their purposes, investigators defined persistent LVEF as less than 45% at least 6 months after implantation of a CRT device, as determined by 3D echocardiography. Authors noted that while MRI may be a more reliable measure of LVEF, both at baseline and endpoint, it was not an option due to the patients' CRT implant. Researchers defined ID as a blood serum ferritin level of less than 100ng/mL, or between 100 and 300ng/mL if transferrin saturation (amount of functional iron in the blood) was under 20%.

At the 3-month conclusion of the study period participants were evaluated by: 3D echocardiogram to assess cardiac structure and function; force-frequency relationship evaluation through noninvasive biventricular pacing; oxygen consumption by means of cardiopulmonary exercise test; Kansas City Cardiomyopathy Questionnaire (KCCQ) score; and blood levels of N-terminal pro B-type natriuretic peptide (a measure of congestive heart failure).

**FINDINGS**

Results from the IRON-CRT trial showed improved cardiac function after FCM treatment for HFrEF patients with ID, CRT implant and persistently reduced LVEF. Participants who received FCM showed significant improvement in LVEF (4.22% increase), force-frequency relationship (0.018 cardiac contractility increase), better peak oxygen consumption (0.87mL/kg/min improvement), and higher KCCQ score (up 1.2 points).

**DISCUSSION**

Iron levels are a well-recognized marker in the pathophysiology of heart failure. Identifying the benefits of intravenous FCM for HFrEF patients with reduced LVEF after CRT implant has valuable implications for patients who have already undergone CRT implantation. This study is the first to suggest that FCM treatment for ID patients with HFrEF improves LVEF and cardiac contractility, however, a larger-scale trial might be needed to further confirm these findings. Additionally, more research is needed to determine whether iron repletion would be beneficial before CRT implant, and for HF patients with preserved ejection fraction (HFPpEF).

Read the full article here: